methyl (2Z)-3-aminopent-2-enoate | 883528-73-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: methyl (2Z)-3-aminopent-2-enoate
• 英文别名: 3-amino-4-methyl crotonic acid methylester；Methyl 3-aminopent-2-enoate；methyl (Z)-3-aminopent-2-enoate
• CAS: 883528-73-2
• 化学式: C₆H₁₁NO₂
• 分子量: 129.159
• InChiKey: NKSXDMWAVIOSTD-PLNGDYQASA-N

物化性质

• 沸点：
  212.5±13.0 °C(Predicted)
• 密度：
  1.007±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl (2Z)-3-aminopent-2-enoate 在 sodium ethanolate 、 potassium carbonate 、 1-羟基苯并三唑 、 caesium carbonate 、 1,2-二氯乙烷 、 三乙胺 、 sodium hydroxide 、 三氯氧磷 作用下， 以 5,5-dimethyl-1,3-cyclohexadiene 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 100.0h， 生成 6-ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide
  参考文献：
  名称：

  Discovery of the investigational drug TAK-441, a pyrrolo[3,2-c]pyridine derivative, as a highly potent and orally active hedgehog signaling inhibitor: Modification of the core skeleton for improved solubility

  摘要：

  We recently reported the discovery of the novel pyrrolo[3,2-c] quinoline-4-one derivative 1 as a potent inhibitor of Hedgehog (Hh) pathway signaling. However, the PK evaluation of 1 at high dosage (100 mg/kg) revealed the C-max value 3.63 mu g/mL, likely due to poor solubility of this compound. Efforts to improve solubility by reducing the aromatic ring count of the core system led to N-methylpyrrolo[3,2-c]pyridine derivative 11. Further optimization of the 3-alkoxy group led to compound 11d with acceptable solubility and potent Hh inhibitory activity. Compound 11d suppressed transcription factor Gli1 mRNA expression in tumor-associated stromal tissue and inhibited tumor growth (treatment/control ratio, 3%) in a mouse medulloblastoma allograft model owing to the improved PK profile based on increased solubility. Compound 11d (TAK-441) is currently in clinical trials for the treatment of advanced solid tumors. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.07.034
• 作为产物：
  描述：

  3-氧代戊酸甲酯 在 ammonium acetate 作用下， 以 甲醇 为溶剂， 生成 methyl (2Z)-3-aminopent-2-enoate
  参考文献：
  名称：

  铜介导的3-氨基丙烯酸烷基酯与芳基重氮盐的快速环化：获得用于药物分子合成的烷基N2-芳基1,2,3-三唑-羧酸盐。

  摘要：

  N-芳基1,2,3-三唑-羧酸烷基酯是药物化学中的重要分子或中间体，但N2-芳基对应物的合成仍然难以捉摸。在本文中，我们描述了3-氨基丙烯酸烷基酯与芳基重氮盐的Cu介导的环化反应，这两种都是容易获得的底物。此外，2-氨基丙烯酸烷基酯也是可行的底物。N 2-芳基1,2,3-三唑-羧酸烷基酯及其类似物可以在温和的条件下快速制备。特别地，该方案允许人们访问碳酸酐酶抑制剂和塞来昔布的几种药物样变体。

  DOI：

  10.1021/acs.orglett.0c00006

文献信息

• [EN] INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS<br/>[FR] COMPOSÉS INDOLIQUES UTILES EN TANT QUE MODULATEURS DU RÉCEPTEUR DES ANDROGÈNES
  申请人：NIDO BIOSCIENCES INC

  公开号：WO2022020342A1

  公开（公告）日：2022-01-27

  Provided herein are compounds of formula (V) that bind to BF3 of an androgen receptor (AR), which can modulate the AR for the treatment of Kennedy's disease.

  本文提供了一种公式（V）的化合物，它们与雄激素受体（AR）的BF3结合，可以调节AR以治疗肯尼迪病。
• Novel radioligands and their use for identifying potassium channel modulators
  申请人：——

  公开号：US20030065182A1

  公开（公告）日：2003-04-03

  The present invention relates to novel radioligands and test methods using those radioligands in screening compounds.

  本发明涉及新型放射配体和使用这些放射配体在筛选化合物中的测试方法。
• [EN] PYRIDINE COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV<br/>[FR] COMPOSES PYRIDINES UTILISES COMME INHIBITEURS DE DIPEPTIDYLE PEPTIDASE IV
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2005042488A1

  公开（公告）日：2005-05-12

  A compound represented by the formula wherein R1 and R2 are the same or different and each is an optionally substituted hydrocarbon group or an optionally substituted hydroxy group; R3 is an optionally substituted aromatic group; R4 is an optionally substituted amino group; L is a divalent chain hydrocarbon group; Q is a bond or a divalent chain hydrocarbon group; and X is a hydrogen atom, a cyano group, a nitro group, an acyl group, a substituted hydroxy group, an optionally substituted thiol group, an optionally substituted amino group or an optionally substituted cyclic group; provided that when X is an ethoxycarbonyl group, then Q is a divalent chain hydrocarbon group. The compound has a peptidase inhibitory action, is useful as an agent for the prophylaxis or treatment of diabetes and the like, and is superior in efficacy, duration of action, specificity, lower toxicity and the like.

  该化合物的化学式表示为其中R1和R2相同或不同，每个都是可选择取代的碳氢基团或可选择取代的羟基团；R3是可选择取代的芳香基团；R4是可选择取代的氨基团；L是二价链状碳氢基团；Q是键或二价链状碳氢基团；X是氢原子、氰基、硝基、酰基、取代的羟基团、可选择取代的硫醇基团、可选择取代的氨基团或可选择取代的环状基团；但当X是乙氧羰基团时，Q为二价链状碳氢基团。该化合物具有肽酶抑制作用，可用作糖尿病等疾病的预防或治疗药物，并在功效、作用持续时间、特异性、毒性较低等方面具有优越性。
• Substituted heteroarylalkanoic acids
  申请人：The Institutes for Pharmaceutical Discovery, Inc. A Corporation of the State of Delaware

  公开号：US20030166668A1

  公开（公告）日：2003-09-04

  Disclosed are substituted heteroarylalkanoic acids acids of the following formula D-A-C(O)R′, where D, A, and R′ are defined herein. These compounds are useful in the treatment of chronic complications arising from diabetes mellitus. Also disclosed are pharmaceutical compositions containing the compounds and methods of treatment employing the compounds, as well as methods for their synthesis.

  揭示了以下公式D-A-C(O)R′的取代杂环烷基丙酸，其中D、A和R′在此处定义。这些化合物在治疗糖尿病引起的慢性并发症方面非常有用。还公开了含有这些化合物的药物组合物以及使用这些化合物的治疗方法，以及它们的合成方法。
• Substituted 6-phenylnicotinic acids and their use
  申请人：Baerfacker Lars

  公开号：US20100234432A1

  公开（公告）日：2010-09-16

  The present application relates to novel substituted 6-phenylnicotinic acid derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prophylaxis of cardiovascular disorders, in particular dyslipidaemias, arteriosclerosis and heart failure.

  本申请涉及新颖的取代6-苯基烟酸衍生物，其制备方法，其用于治疗和/或预防疾病的用途以及用于制备治疗和/或预防疾病的药物的用途，特别是用于治疗和/或预防心血管疾病，特别是血脂异常、动脉硬化和心力衰竭的用途。